Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares Outstanding
Ratios

Sanofi (SNY) EBIAT (2016 - 2026)

Sanofi's EBIAT history spans 16 years, with the latest figure at $1.9 billion for Q1 2026.

  • On a quarterly basis, EBIAT fell 4.75% to $1.9 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $8.7 billion, a 28.75% increase, with the full-year FY2025 number at $9.1 billion, up 53.98% from a year prior.
  • EBIAT hit $1.9 billion in Q1 2026 for Sanofi, up from -$7.7 billion in the prior quarter.
  • Over the last five years, EBIAT for SNY hit a ceiling of $10.1 billion in Q3 2025 and a floor of -$7.7 billion in Q4 2025.
  • Historically, EBIAT has averaged $1.8 billion across 5 years, with a median of $2.0 billion in 2025.
  • The widest YoY moves for EBIAT: up 271.15% in 2025, down 1715.95% in 2025.
  • Tracing SNY's EBIAT over 5 years: stood at $3.2 billion in 2022, then crashed by 129.83% to -$964.0 million in 2023, then soared by 149.55% to $477.7 million in 2024, then tumbled by 1715.95% to -$7.7 billion in 2025, then soared by 124.57% to $1.9 billion in 2026.
  • Business Quant data shows EBIAT for SNY at $1.9 billion in Q1 2026, -$7.7 billion in Q4 2025, and $10.1 billion in Q3 2025.